Hua Chun-Zhen, Hu Wei-Lin, Shang Shi-Qiang, Li Jian-Ping, Hong Li-Quan, Yan Jie
Division of Infectious Diseases, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Department of Medical Microbiology and Parasitology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China Division of Basic Medical Microbiology, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Clin Vaccine Immunol. 2015 Dec 16;23(2):155-61. doi: 10.1128/CVI.00506-15. Print 2016 Feb.
Nontypeable Haemophilus influenzae (NTHi) is one of the most common etiologies of acute otitis media, rhinosinusitis, and pneumonia. Outer membrane proteins (OMPs) are the main focus in new vaccine development against NTHi, as the H. influenzae type b (Hib) vaccine does not cover noncapsulated NTHi. The OMPs P6 and protein D are the most promising candidate antigens for an NTHi vaccine, and low antibody levels against them in serum may be correlated with infection caused by NTHi. In the current study, we measured the antibody titers against P6, protein D, and their T- and B-cell combined peptide epitopes in healthy individuals of different ages. We found that children <1 month old had the lowest antibody levels against NTHi P6, protein D, and their T- and B-cell combined antigenic epitopes. Antibody titers increased at ages 1 to 6 months, peaked at 7 months to 3 years, and remained high at 4 to 6 years. The antibody titers started to decrease after 6 years and were the lowest in the 21- to 30-year group. The geometric mean titers (GMTs) of T- and B-cell combined antigenic epitopes in P6 and protein D were positively correlated with those of the protein antigens. Among 12 peptides tested, P6-61, P6-123, and protein D-167 epitopes were better recognized than others in human serum. These findings might contribute to the development of an effective serotype-independent vaccine for H. influenzae.
非分型流感嗜血杆菌(NTHi)是急性中耳炎、鼻窦炎和肺炎最常见的病因之一。外膜蛋白(OMPs)是新型NTHi疫苗研发的主要焦点,因为b型流感嗜血杆菌(Hib)疫苗不能覆盖无荚膜的NTHi。OMPs P6和蛋白D是NTHi疫苗最有前景的候选抗原,血清中针对它们的低抗体水平可能与NTHi引起的感染相关。在本研究中,我们测量了不同年龄健康个体中针对P6、蛋白D及其T细胞和B细胞联合肽表位的抗体滴度。我们发现,1个月以下的婴儿针对NTHi P6、蛋白D及其T细胞和B细胞联合抗原表位的抗体水平最低。抗体滴度在1至6个月龄时升高,在7个月至3岁时达到峰值,并在4至6岁时保持较高水平。6岁后抗体滴度开始下降,在21至30岁组中最低。P6和蛋白D中T细胞和B细胞联合抗原表位的几何平均滴度(GMTs)与蛋白抗原的GMTs呈正相关。在测试的12种肽中,P6-61、P6-123和蛋白D-167表位在人血清中比其他表位更易被识别。这些发现可能有助于开发一种有效的非血清型流感嗜血杆菌疫苗。